Trialect

Active

Notice of Special Interest (NOSI): Optimizing Vascularized Composite Allograft Survival

National Institutes of Health

The National Institute of Allergy and Infectious Diseases (NIAID) is interested in supporting preclinical studies utilizing animal models or human tissue specimens that focus on 1) optimizing treatment and graft monitoring to reduce incidence of acute rejection and maximize graft survival after vascularized composite allotransplantation (VCA) and 2) minimizing immunosuppression required for long-term VCA acceptance.

The objective of this Notice of Special Interest (NOSI) is to encourage preclinical research in animal models of VCA or human composite tissue specimens that focus on 1) understanding immune mechanisms of rejection and tolerance and 2) the development of therapeutic and monitoring approaches that address the unique vulnerabilities and opportunities of face, limb, and abdominal wall vascularized composite allografts. The overarching goal is to expand clinical opportunities and improve outcomes for these life-enhancing procedures.

This NOSI will support applications that use human specimens and/or rodent, porcine, or nonhuman primate transplant models to develop novel therapeutic approaches to reduce acute rejection and maximize VCA survival and/or minimize immunosuppression required for long-term VCA acceptance. In addition to immunologic assays, an assessment of strength or weightbearing ability (if applicable), nerve regeneration, and susceptibility/resistance to infection may be appropriate. Incorporation of cutting-edge technologies and interdisciplinary collaborations are encouraged to adequately address the immunological and physiological complexities of these multi-component grafts.

This notice applies to due dates on or after June 5, 2022 and subsequent receipt dates through May 7, 2026.

NOT-AI-22-023

Specialties

Medical

Medical - Clinical Science

Medical - Basic Science

Medical - Translational

Eligibility Requirements

Only existing CCRP-funded/co-funded awardees funded by these Funding Opportunity Announcements or any reissues of these announcements through the expiration of this Notice, are eligible to apply:

PAR-16-329 , PAR-16-330 , PAR-16-331 , PAR-18-657 , PAR-19-039 , PAR-19-040 , and PAR-20-316

Active awards cannot be in the first or last 12 months of the Project Period, exclusive of time in no-cost extension (NCE), at the time of the due date will be considered. Awards in NCE are ineligible to apply.
Grantee organizations may submit more than one application, provided that each application is distinct from other administrative supplements or other types of grant applications already funded or under consideration by the NIH.